15. NMA results for PFS (MSKCC intermediate and poor risk groups).

Results of network meta‐analysis for outcome progression‐free survival (MSKCC intermediate and poor risk groups). Treatments are ordered by P‐Score (descending). Only subnetworks with >1 designs. Upper triangle: direct estimate. Lower triangle: network estimate. Subnet 1 No. of studies: 10. No. of pairwise comparisons: 10. No. of treatments: 6. No. of designs: 5 Heterogeneity/Inconsistency: Q = 14.40, df = 5, P = 0.013; I² = 65.3%, Tau² = 0.1433 Treatment Effects + 95%‐CIs (Hazard ratios, random‐effects model):
LEN+PEM	.		.	0.33 [0.17, 0.62]		.	.
0.45 [0.19, 1.10]	LEN+EVE		.	0.72 [0.39, 1.33]		.	.
0.34 [0.09, 1.32]	0.76 [0.20, 2.88]		AXI	.		0.83 [0.35, 1.96]	.
0.33 [0.17, 0.62]	0.72 [0.39, 1.33]		0.95 [0.29, 3.08]	SUN		0.88 [0.39, 1.97]	0.84 [0.52, 1.34]
0.29 [0.10, 0.81]	0.63 [0.23, 1.75]		0.83 [0.35, 1.96]	0.88 [0.39, 1.97]		SOR	.
0.27 [0.12, 0.61]	0.60 [0.28, 1.31]		0.79 [0.22, 2.82]	0.84 [0.52, 1.34]		0.95 [0.37, 2.43]	EVE
Subnet 2 No. of studies: 2. No. of pairwise comparisons: 2. No. of treatments: 3. No. of designs: 2 Heterogeneity/Inconsistency: Q = 2.79, df = 2, P = 0.247; I²=28.3%, Tau² = 0.0175 Treatment Effects + 95%‐CIs (Hazard ratios, random‐effects model):
IFN+BEV		0.99 [0.74, 1.32]			0.60 [0.45, 0.82]
0.99 [0.74, 1.32]		TEM+BEV			.
0.60 [0.45, 0.82]		0.61 [0.40, 0.93]			IFN+PLA